Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Age |
|
At Baseline |
|
Primary |
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Age group |
|
At Baseline |
|
Primary |
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Gender |
|
At Baseline |
|
Primary |
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Index month |
|
At Baseline |
|
Primary |
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Height |
|
At Baseline |
|
Primary |
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Weight |
|
At Baseline |
|
Primary |
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Body Mass Index (BMI) |
|
At Baseline |
|
Primary |
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Treatments |
|
At Baseline |
|
Primary |
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Comorbidities |
|
At Baseline |
|
Primary |
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Follow-up |
|
At Baseline |
|
Primary |
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: History of thrombosis |
|
At Baseline |
|
Primary |
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Charlson Comorbidity Index (CCI) |
|
At Baseline |
|
Primary |
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: CCI severity |
|
At Baseline |
|
Primary |
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Molecular/diagnosis testing |
|
At Baseline |
|
Primary |
Distribution of the use of treatments for COVID-19: Anticoagulation |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19: Angiotensin-converting enzyme (ACE) inhibitors |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19: Angiotensin II receptor blockers (ARBs) |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19: ARBs combination |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19: Statin |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19: HIV protease inhibitor |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19: Non-pharmacological treatment |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19 symptoms: Anticoagulation |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19 symptoms: Angiotensin-converting enzyme (ACE) inhibitors |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19 symptoms: Angiotensin II receptor blockers (ARBs) |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19 symptoms: ARBs combinations |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19 symptoms: Statin |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19 symptoms: HIV protease inhibitor |
|
Up to 9 months |
|
Primary |
Distribution of the use of treatments for COVID-19 symptoms: Non-pharmacological treatment |
|
Up to 9 months |
|
Primary |
Distribution of composite outcomes of COVID-19 patients: In-hospital death |
|
Up to 9 months |
|
Primary |
Distribution of composite outcomes of COVID-19 patients: Overall survival |
|
Up to 9 months |
|
Primary |
Distribution of composite outcomes of COVID-19 patients: Utilization of Extracorporeal membrane oxygenation (ECMO) |
|
Up to 9 months |
|
Primary |
Distribution of composite outcomes of COVID-19 patients: Utilization of mechanical ventilation (invasive & noninvasive) |
|
Up to 9 months |
|
Primary |
Distribution of composite outcomes of COVID-19 patients: Utilization of oxygen therapy |
|
Up to 9 months |
|
Primary |
Distribution of composite outcomes of COVID-19 patients: Intensive care unit/high care unit (ICU/HCU) admission |
|
Up to 9 months |
|
Secondary |
Distribution of composite outcomes of COVID-19 patients treated with anticoagulant therapy during the follow-up period |
Severity of COVID-19 |
Up to 9 months |
|
Secondary |
Distribution of composite outcomes of COVID-19 patients treated without anticoagulant therapy during the follow-up period |
Severity of COVID-19 |
Up to 9 months |
|